Clopidogrel-aspirin dual antiplatelet therapy in stable CAD patients attenuates platelet sCD40L release without affecting post-vascular injury thrombin generation, while clopidogrel monotherapy similarly reduces sCD40L (84–86). The gene discussed is CD40LG; the disease is coronary artery disorder.